- Home
- JYD vs CLDI Comparison
JYD vs CLDI Comparison
Compare JYD & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | CLDI |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 8.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | JYD | CLDI |
|---|---|---|
| Price | $3.97 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 99.7K | 84.3K |
| Earning Date | 04-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,305,742.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.71 | $1.01 |
| 52 Week High | $400.00 | $19.20 |
Technical Indicators
Market Signals| Indicator | JYD | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 29.92 |
| Support Level | $3.79 | $1.05 |
| Resistance Level | $4.95 | $1.16 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 6.15 | 13.04 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.